752986
Last Update Posted: 2016-12-05
Recruiting has ended
Females accepted | 45 Years + |
39 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
The primary objective is to assess the event-free survival defined as the time from randomisation to progression, death without progression, loss to follow up, whichever occurred first..
end-point Efficacy: event-free survival (EFS)
Eligibility
Relevant conditions:
Breast Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov